LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway
P Du, H Zhao, R Peng, Q Liu, J Yuan, G Peng… - Bioscience …, 2017 - portlandpress.com
Temozolomide (TMZ) is the most commonly used alkylating agent in glioma chemotherapy.
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …
However, growing resistance to TMZ remains a major challenge for clinicians. Recent …
Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152
Y Yao, J Ma, Y Xue, P Wang, Z Li, J Liu, L Chen, Z Xi… - Cancer letters, 2015 - Elsevier
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Great interest
persists in useful therapeutic targets in GBM. Aberrant expression of long non-coding RNAs …
persists in useful therapeutic targets in GBM. Aberrant expression of long non-coding RNAs …
lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2‐mediated PI3K/AKT pathway in glioma
The discovery of long noncoding RNAs (lncRNAs) has improved the understanding of
development and progression in various cancer subtypes. However, the role of lncRNAs in …
development and progression in various cancer subtypes. However, the role of lncRNAs in …
[PDF][PDF] Overexpression of XIST facilitates cell proliferation, invasion and suppresses cell apoptosis by reducing radio-sensitivity of glioma cells via miR-329-3p/CREB1 …
YP Wang, HQ Li, JX Chen, FG Kong… - European Review for …, 2020 - europeanreview.org
OBJECTIVE: Glioma is a malignant brain cancer capable of spreading to the
microenvironment. Long non-coding RNA (lncRNA) X inactive specific transcript (XIST) was …
microenvironment. Long non-coding RNA (lncRNA) X inactive specific transcript (XIST) was …
LINC00174 down-regulation decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis
B Li, H Zhao, J Song, F Wang, M Chen - Human Cell, 2020 - Springer
Temozolomide (TMZ) is one of the most common drugs selected for glioma chemotherapy,
but the therapeutic effect of glioma treatment is usually limited due to its resistance. Long …
but the therapeutic effect of glioma treatment is usually limited due to its resistance. Long …
lncRNA XIST promotes glioma proliferation and metastasis through miR‑133a/SOX4
C Luo, Z Quan, B Zhong, M Zhang… - Experimental and …, 2020 - spandidos-publications.com
Glioma is the most common malignant brain tumour in adults, and the aetiology and
mechanism of this tumour remain largely unknown. Previous studies have demonstrated that …
mechanism of this tumour remain largely unknown. Previous studies have demonstrated that …
[HTML][HTML] Long noncoding RNA RP11-838N2. 4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines
Y Liu, N Xu, B Liu, Y Huang, H Zeng, Z Yang, Z He… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Resistance to temolozomide (TMZ), the standard chemotherapy agent for treating
glioblastomas (GBM), is a major clinical problem for patients with GBM. Recently, long …
glioblastomas (GBM), is a major clinical problem for patients with GBM. Recently, long …
LINC00511 facilitates Temozolomide resistance of glioblastoma cells via sponging miR‐126‐5p and activating Wnt/β‐catenin signaling
Y Lu, M Tian, J Liu, K Wang - Journal of Biochemical and …, 2021 - Wiley Online Library
Temozolomide (TMZ) is the first‐line chemotherapy drug for glioblastoma (GBM) but
acquired TMZ resistance is frequently observed. Thus, a TMZ resistant GBM cell line U87‐R …
acquired TMZ resistance is frequently observed. Thus, a TMZ resistant GBM cell line U87‐R …
LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma
X He, J Sheng, W Yu, K Wang, S Zhu, Q Liu - Cellular and molecular …, 2021 - Springer
Temozolomide (TMZ) is widely used for glioma therapy in the clinic. Currently, the
development of TMZ resistance has largely led to poor prognosis. However, very little is …
development of TMZ resistance has largely led to poor prognosis. However, very little is …
MicroRNA-195 reverses the resistance to temozolomide through targeting cyclin E1 in glioma cells
H Wang, S Ren, Y Xu, W Miao, X Huang, Z Qu… - Anti-cancer …, 2019 - journals.lww.com
Glioma is the most common malignant tumor of the central nervous system with poor
survival. Temozolomide (TMZ) is the first-line chemotherapy drug for initial and recurrent …
survival. Temozolomide (TMZ) is the first-line chemotherapy drug for initial and recurrent …